DeepScribe vs Nabla (2026)
Both are enterprise scribes with real independent signal, pointed at different problems. DeepScribe built for complex specialty medicine: oncology as its center of gravity with a reported 40 percent of US cancer care visits, tuned models for six further specialties, more than 110 languages, and the highest independent rating in the lane at 98.8 on the KLAS Emerging Company Spotlight. Nabla built for the estate: named integrations across Epic, athenahealth, Oracle Health, NextGen, and Greenway, the widest footprint relative to this pairing, with a customer base weighted toward hospital systems and emergency departments and efficiency figures attributed to a published NEJM study. If your failure mode is specialty documentation that generalist scribes get wrong, oncology above all, start with DeepScribe. If your failure mode is a mixed EHR environment or an emergency and hospital medicine base that one contract has to cover, start with Nabla, and confirm its training default and BAA tier before deployment. Neither currently publishes pricing.
- Specialty depth is the requirement: oncology first with a reported 5 million oncology visits a year and roughly 40 percent of US cancer care visits documented, plus tuned models for cardiology, urology, gastroenterology, orthopedics, neurology, and nephrology.
- The evidence grades split in its favor: an A against Nabla's B, on a 98.8 KLAS Emerging Company Spotlight score with A plus marks across all six categories and an August 2025 Journal of Clinical Pathways study in oncology, where Nabla's NEJM attributed figures are held at B because study design and cohort were not captured.
- Language and write back depth: conversations in more than 110 languages against Nabla's roughly 31, with bidirectional integration writing structured data into discrete EHR fields and HCC, CPT, and ICD-10 suggestions built into the note.
- Estate coverage decides it: named integrations across Epic, athenahealth, Oracle Health, NextGen, and Greenway, where DeepScribe's integrations run Epic, athenahealth, NextGen, and eClinicalWorks; the Oracle Health and Greenway reach matters for mixed hospital and ambulatory environments.
- Your base looks like its base: more than 85,000 clinicians at over 150 organizations, weighted toward hospital systems, emergency departments, and multi provider groups, across in person and telehealth encounters.
- General coverage rather than specialty tuning: templates across more than 35 specialties customized through custom instructions and dot phrases, a fit for organizations whose documentation load is broad rather than concentrated in complex specialty care.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. DeepScribe and Nabla are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | DeepScribe | Nabla |
|---|---|---|
| Primary category | Ambient Scribes | Ambient Scribes |
| Founded | 2017 | 2018 |
| Headquarters | San Francisco, California | Paris, France |
| Website | deepscribe.ai | nabla.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards DeepScribe its top capability grade on several axes, including AI Centrality, Clinical and Operational Evidence and EHR and Interoperability Depth. Set against Nabla, DeepScribe grades higher on HIPAA and BAA Posture. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, July 2026
The AI Health Index awards Nabla its top capability grade on several axes, including AI Centrality, Clinical and Operational Evidence and AI Safety and PHI Stewardship. Set against DeepScribe, Nabla grades higher on Model Supply Chain Disclosure, AI Safety and PHI Stewardship and Security Certifications and Trust Center. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, July 2026
Questions buyers ask
Should we choose DeepScribe or Nabla?
On the axes where the AI Health Index separates them, DeepScribe grades higher on HIPAA and BAA Posture, and Nabla grades higher on Model Supply Chain Disclosure, AI Safety and PHI Stewardship and Security Certifications and Trust Center. Nabla leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do DeepScribe and Nabla differ most?
The widest separation the AI Health Index records between DeepScribe and Nabla is on AI Safety and PHI Stewardship, where DeepScribe grades C and Nabla grades A. That axis sits in the AI Capability group, so it should carry the most weight for a buyer whose binding constraint is how much of the work the model itself is trusted to do.
Where do DeepScribe and Nabla grade the same?
The AI Health Index grades DeepScribe and Nabla the same on several axes, including AI Centrality, Autonomy and Oversight Model and Model and Technology Transparency. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Ambient Scribes page.
Visit volumes and market share figures for both vendors are vendor published, including DeepScribe's oncology share and Nabla's clinician count. DeepScribe's KLAS scores are buyer survey based, and the Emerging Company Spotlight is a different KLAS instrument from the Best in KLAS category awards held elsewhere in this lane. Nabla's evidence grade is held at B because the design and cohort of the NEJM study it cites were not captured in retrieved materials.
Two Nabla caveats matter for procurement: the free tier reportedly lacks a Business Associate Agreement, and session data is used for model training by default; confirm both, and whether training can be disabled contractually, before deployment. Neither vendor currently publishes pricing.
Third party estimates place DeepScribe at $350 to $500 per provider per month with some reports near $750; Nabla previously published tiers, including a Pro plan reported near $119 per month, and has withdrawn them toward contract sales. All estimates are unconfirmed.